ArticleMedical physics2026
Lighting up FLASH and beyond: TLD response across four orders of magnitude in proton dose rate.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThermoluminescent dosimeters (TLDs) are widely used for proton therapy dosimetry and remote audits. Yet their response under pulsed delivery and the ultrahigh dose rates relevant to proton FLASH remains incompletely characterized. In proton beams, apparent dose-rate effects can be masked by changes in linear energy transfer (LET), so we designed measurements to separate true dose-rate dependence from LET-driven changes in TLD sensitivity. PURPOSE: To characterize TLD-100 (LiF:Mg,Ti) detector response to synchrotron-based proton beams across in-pulse dose rates spanning approximately 0.1 to 2000 Gy/s.
methodsTLD-100 powder capsules were irradiated in the entrance region of 87.2 MeV protons using two Hitachi ProBeat synchrotron beamlines: a clinical spot-scanning beamline (0.3 Gy/s in-pulse) and an experimental beamline (approximately 0.1-2000 Gy/s). Three dose levels (3, 9, and 18 Gy) were evaluated across three experimental sessions. Expected doses to TLDs were calculated using benchmarked Geant4 Monte Carlo models. In-pulse dose rates were determined from dose per pulse divided by pulse duration. Pulse duration was measured using an oscilloscope for all dose rates. For dose rates ≤375 Gy/s, dose per pulse was measured using an Advanced Markus ion chamber (P
resultsTLD response demonstrated systematic in-pulse dose-rate dependence with three distinct regions. At in-pulse dose rates below 7 Gy/s, TLDs exhibited 1%-7% over-response attributed to efficient charge carrier trapping. Near-unity response (0%-5%) was observed between 7-300 Gy/s, representing balanced trapping and recombination. Above 300 Gy/s, TLDs showed 1%-7% under-response due to enhanced electron-hole recombination. Two-way ANOVA confirmed in-pulse dose rate as the dominant factor (82.9% of variance, p < 0.0001), while dose had minimal effect (2.3% of variance). One-way ANOVA with Šídák's test showed no significant difference among dose levels (p > 0.05), confirming dose independence across 3-18 Gy.
conclusionTLD-100 response to synchrotron-based protons is dose-independent across 3-18 Gy but follows a characteristic in-pulse dose-rate profile governed by charge carrier dynamics: over-response between 0.1-7 Gy/s, nearly unity between 7-300 Gy/s, and under-response between 300-2000 Gy/s.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.